Skip to main content
Last Updated
Case Status
In the Matter of Amgen, Inc., a corporation, and Horizon Therapeutics plc, a corporation
FTC Matter/File Number
231 0037
Docket Number
Enforcement Type
Part 3 Administrative Complaints

Case Summary

In August 2023, the FTC reached a proposed consent order with Amgen Inc. to address the potential competitive harm that would result from Amgen’s $27.8 billion acquisition of Horizon Therapeutics plc. As part of a nationwide settlement of their challenge to the acquisition, the FTC and attorneys general from six states – California, Illinois, Minnesota, New York, Washington, and Wisconsin – also dismissed the related federal court preliminary injunction action, allowing the transaction to proceed, with the conditions imposed by the order. In December 2023, the FTC finalized the consent order with Amgen Inc. and appointed a monitor.

Case Timeline